BioQuiddity Changes Name to BioQ Pharma

SAN FRANCISCO, Oct. 27, 2015 (GLOBE NEWSWIRE) — BioQuiddity Incorporated (“the Company” or “BioQ”), a specialty pharmaceutical company focused on the development and commercialization of large volume ready-to-use infusible pharmaceuticals, announced today that it has changed its corporate name to BioQ Pharma to better reflect the Company’s evolution as a specialty pharmaceutical company with a late-stage pipeline of infusible pharmaceutical products and product candidates.

Josh Kriesel, President and CEO of BioQ Pharma, commented, “BioQ has made great strides over the last year solidifying commercial collaborations with some of the world’s leading multinational pharmaceutical companies, including Sandoz, Cipla and Lee’s Pharm. As the Company continues to advance its late-stage pipeline and commercialize its ready-to-use infusible pharmaceuticals, our new name more accurately reflects our business plan. BioQ Pharma intends to be a best-in-class specialty pharmaceutical company that is setting a new standard of care in the presentation and administration of infusible drugs.”

In conjunction with the Company’s name change, BioQ Pharma has launched a new corporate website. Please follow the link below to learn more:

www.bioqpharma.com

About BioQ Pharma

BioQ Pharma (formerly known as BioQuiddity Incorporated) is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company’s infusion platform addresses some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma’s vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company’s proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma’s commercial collaborators and strategic partners include Novartis’ Sandoz unit, Cipla, Lee’s Pharmaceutical and West Pharmaceutical Services.

CONTACT: Company Contact Information:

         Josh Kriesel
         President and CEO
         415-336-6496
         
         Ron Pauli
         Chief Financial Officer
         415-889-7707
         
         Media:

         Stephanie Carrington
         Integrated Corporate Relations, Inc (ICR)
         stephanie.carrington@icrinc.com
         646-277-1282

Left Menu Icon
Right Menu Icon